PLOS ONE

Prognostic value of preoperative circulating tumor cells counts in patients with UICC stage I-IV colorectal cancer

Thaer S. A. Abdalla[ORCID]1*, Jan Meiners1, Sabine Riethdorf2, Alexandra König3, Nathaniel Melling1, Tobias Gorges2, Karl-F. Karstens1, Jakob R. Izbicki1, Klaus Pantel2, Matthias Reeh1

1 Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2 Department of Tumor Biology, University Cancer Center Hamburg, Center for Experimental Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3 Department of General Surgery, Hospital Wilhelmshaven, Wilhelmshaven, Germany

* t.abdalla@uke.de

Abstract

Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide. There is an urgent need to identify prognostic markers for patients undergoing curative resection of CRC. The detection of circulating tumor cells in peripheral blood is a promising approach to identify high-risk patients with disseminated disease in colorectal cancer. This study aims to evaluate the prognostic relevance of preoperative CTCs using the Cellsearch® system (CS) in patients, who underwent resection with curative intent of different stages (UICC I-IV) of colorectal cancer. Out of 91 Patients who underwent colorectal resection, 68 patients were included in this study. CTC analysis was performed in patients with CRC UICC stages I-IV immediately before surgery. Data were correlated with clinicopathological parameters and patient outcomes. One or more CTCs/7.5 mL were detected in 45.6% (31/68) of patients. CTCs were detected in all stages of the Union of International Cancer Control (UICC), in stage I (1/4, 25%), in stage II (4/12, 33.3%), in stage III (5/19, 26.3%) and in stage IV (21/33, 63.6%). The detection of $\geq$ 1 CTCs/ 7.5ml correlated to the presence of distant overt metastases (p = 0.014) as well as with shorter progression-free (p = 0.008) and overall survival (p = 0.008). Multivariate analyses showed that the detection of $\geq$ 1 CTCs/ 7.5ml is an independent prognostic indicator for overall survival (HR, 3.14; 95% CI, 1.18–8.32; p = 0.021). The detection of CTCs is an independent and strong prognostic factor in CRC, which might improve the identification of high-risk patients in future clinical trials.

Introduction

Colorectal cancer (CRC) is the 3rd most diagnosed cancer and the 4th leading cause of death in the world with 1.3 million new cases annually [1]. Two-thirds of the patients with CRC present with localized and potentially curable disease at diagnosis (TNM Stage I-III) [2]. In these patients, surgery remains the most important treatment modality.

Currently, the overall 5-year survival is 65% [1, 2]. This increased over the last four decades after the introduction of screening programs and the concept of adjuvant chemotherapy [3, 4].

The surgical technique also evolved with the introduction of total mesorectal excision (TME) for rectal cancer and central venous ligature (CVL) with complete mesocolic excision (CME) for colon cancer, where sharp dissection in the embryological planes increases lymph node yields, subsequently improving staging and survival [5, 6]. Nevertheless, tumor recurrence or spread to distant sites and formation of metastases still occur in 20% of the patients and is the leading cause of death in these patients [7]. Even in patients with apparently early stages TNM (I-II), local recurrence or distant metastases occur despite proper treatment [8].

Tumor persistence and progression occur mainly due to circulating tumor cells (CTCs) which are seeded from the primary tumor and target distant organs, where they eventually mature and cause secondary metastasis [9]. Preoperative identification of CTCs through liquid biopsy is of proven utility in predicting prognosis in breast, colon, and prostate cancer [10–12].

The 8th AJCC Cancer Staging Manual expanded the definitions of Tis, T4a, and M1 and nodal micrometastasis in CRC [13]. However, unlike in breast cancer, new staging categories like M0 (i+), in which CTC or disseminated tumor cells in the bone marrow are detected, are still lacking [14].

Identifying CTCs preoperatively in liquid biopsies could provide information to solve common dilemmas in CRC [15], like patient selection for adjuvant chemotherapy in stage II CRC after tumor resection.

Isolation and molecular analysis of CTCs in peripheral blood are promising approaches to identify disseminated disease, to upgrade or downgrade the multimodal therapy. The Cell-Search® (CS) (Menarini, Silicon Biosystems, Bologna, Italy), a known method for quantification of CTCs based on the expression of the epithelial cell adhesion molecule (EpCAM) and of keratin, is the first standardized system approved by the U.S. Food and Drug Administration for capturing and detection of CTCs derived from metastatic breast and prostate cancer as well as metastatic CRC [10, 16].

The aim of this study is to assess the preoperative value of CTCs in different stages of CRC on the overall survival and progression-free survival using CS.

Materials and methods

This prospective study was conducted at the University Hospital Hamburg-Eppendorf in Germany. The study was approved by the medical ethics committee of the Chamber of Physicians of Hamburg. All patients gave their written informed consent for inclusion before they participated in the study. The study was conducted in accordance with the Declaration of Helsinki.

The inclusion criteria were: 1) adult patients ($\geq$ 18 years) and 2) presence of a primary resectable CRC. Patients with synchronous malignancy were excluded. Also, patients with resectable metachronous metastasis of CRC or local recurrence were excluded (Fig 1). Out of the 91 patients who underwent colorectal resection, 68 were eligible for inclusion in this study.

Peripheral blood samples for CTC analysis were collected immediately before surgery and within the first 96 hours postoperatively. Follow up was conducted according to S3 German Guidelines [17]. Events considered were death, local recurrence, and distant metastasis. Overall survival was the time from operation to death or last follow-up, and progression-free survival was defined as the time from operation to the diagnosis of tumor recurrence.

CTC analysis

CTC analysis was performed using CS as previously described [18]. Blood samples (7.5 mL) were collected in CellSave preservative tubes, stored at room temperature, and processed within 96 hours after blood collection, according to the manufacturer's instructions. The

Fig 1. Flow chart. Process of patient selection.

accuracy and reproducibility of CS have been described previously [18, 19]. The presence of a nucleus, cytokeratin expression, round or oval cell morphology of cells with a diametre of at lest 4 μm, and absence CD45 expression served as the criteria for CTCs [18].

Statistical analysis

SPSS statistic software version 25 was used. Histological characteristics were expressed as descriptive statistics. The x^2 was used to investigate the association between CTCs and histo-pathological parameters. Survival rates were determined using the Kaplan–Meier method and were compared using the log-rank test. A multivariate analysis of factors that might influence OS was performed using the Cox proportional hazards regression model. The results were presented as hazard ratios with 95% CI. All comparisons were two-tailed. A *p*-value of less than 0.05 was considered statistically significant. All authors had access to the study data and had reviewed and approved the final manuscript.

Results

Patient characteristics and CTC detection

CTC analysis was performed in blood samples from 68 patients preoperatively. 38 patients had CTC analysis within the first 96 hours after the procedure. Forty-three patients were nodal positive. Distant metastasis was present in 34 patients at the time of operation (Table 1).

The median age of patients was 64.7 years (range, 18–88 years). Applying a cut-off of ≥ 1 CTC, 31 out of 68 (45%) patients were CTC-positive preoperatively and 13 out of 38 (19.1%)

Table 1. Site of metastasis.

Site of Metastasis	Number of Patients
Lungs	4
Liver	21
Peritoneum	9

patients were CTC-positive postoperatively. In 8 out of 13 patients, CTCs were also present preoperatively.

We assessed the correlation between CTC detection preoperatively with sex, age and the following histopathologic parameters: Grade of differentiation (G), tumor Invasion (T), nodal status (N), metastases (M), Union of International cancer control (UICC-Stage), HER2, KRAS, MSI mutations and tumor location (Table 2). The detection of CTCs was related to the

Table 2. Patient characteristics and correlation of CTCs at baseline with clinicopathological parameters.

Variables	Preoperative $\geq$ 1 CTC		
	All	**CTC-Positive**	**p-value**
All	68	31 (45.6%)	
Age			0.812
<65	20	8 (40%)	
65–74	28	13 (46.4%)	
$\geq$75	20	10 (50%)	
Sex			0.320
Male	44	18 (40.9%)	
Female	24	13 (54.2%)	
Grade			0.636
G1	1	0 (0%)	
G2	48	23 (49.9%)	
G3	13	6 (46.2%)	
No Grading*	6		
Tumor size			0.270
T1	3	0 (0%)	
T2	8	4 (50%)	
T3	38	16 (42.1%)	
T4	19	11 (57.9%)	
Nodal status			0.707
N0	25	12 (48%)	
N1	14	5 (35.7%)	
N2	29	14 (48.3%)	
Metastatic stage			0.014
M0	34	10 (29.4%)	
M1	34	21 (61.8%)	
UICC Stage			0.065
Stage I	4	1 (25%)	
Stage II	12	4 (33.3%)	
Stage III	18	5 (27.8%)	
Stage IV	34	21 (61.8%)	
Tumor site			0.291
Right side	22	9 (40.9%)	

(*Continued*)

Table 2. (Continued)

Variables	Preoperative ≥ 1 CTC		
	All	**CTC-Positive**	***p*-value**
Left side	14	8 (57.1%)	
Rectum	32	18 (56.2%)	
HER2-Mutation			0.483
Negative	44	22(50%)	
Positive	4	2 (50%)	
Missing	20	7 (35%)	
KRAS-Mutation			0.345
Negative	24	10 (41.7%)	
Positive	29	16(55.2%)	
Missing	15	5 (33.3%)	
MSI			0.718
Present	5	2 (40%)	
not present	25	13 (52%)	
Missing	38	16 (42.1%)	

P-value Indicates significance according to the χ2 test when CTC-negative patients are compared with CTC-positive patients. Round parentheses indicate percentages. No Grading* after radiotherapy for rectal cancer, instead of Dworak's system of tumor regression

https://doi.org/10.1371/journal.pone.0252897.t002

presence of distant metastases *(p = 0.014)* and showed a tendency towards the Union of International cancer control stage *(p = 0.065)*. Other parameters did not significantly correlate with CTC positivity preoperatively. Postoperatively, CTC detection did not correlate with any of the above-mentioned parameters.

Univariate and multivariate analysis of survival

The median survival time was 32 months. Kaplan-Meier's univariate analysis showed that patients with ≥ 1 CTC had significantly shorter progression-free ($p = 0.008$) as well as overall survival ($p = 0.008$) compared to CTC-negative patients (Fig 2). Also, the presence of distant metastases at baseline was associated with shorter OS (*p*-value 0.002) and shorter PFS (*p*-value < 0.001) (Fig 3). However, postoperative CTCs did not correlate with OS (*p*-value = 0.829) and PFS (*p*-value 0.876) (Fig 4).

Nine clinicopathological factors were analyzed using Cox-Regression analysis. Only 4 factors correlated with survival in univariate analysis (Table 3). These included age, metastatic disease, UICC stage, preoperative CTC detection ($p < 0.05$). Gender, postoperative CTC detection, and other factors were not related to survival in the univariate analysis. The four factors significantly related to survival in univariate analysis were evaluated in the multivariate analysis, which showed that only advanced age and preoperative CTC detection were independent prognosticators of an unfavorable OS (Table 3).

Discussion

Despite advances in multimodal treatment, CRC is the second most common cause of cancer death worldwide [1]. CTCs play a pivotal role in disease progression, metastasis, and recurrence [20]. Aside from TNM classification and status of resection margin, novel tools and staging systems are needed for adequate prognostic staging and for guiding multimodal therapy

	Log-Rank (Mantel-Cox)	
	Chi-Square	p-value
Figure A (OS)	6.962	0.008
Figure B (PFS)	7.072	0.008

Fig 2. Kaplan-Meier survival analysis for overall survival and progression-free survival according to the preoperative CTCs. (a): Overall survival in patients with CRC, positive vs. negative preoperative CTCs. (b): Progression-free survival in patients with CRC, positive vs. negative preoperative CTCs. *P*-value Indicates significance according to Log-Rank (Mantel-Cox) test when CTC-negative patients are compared with CTC-positive patients preoperatively.

	Log-Rank (Mantel-Cox)	
	Chi-Square	p-value
Figure a (OS)	9.262	0.002
Figure b (PFS)	12.447	< 0.001

Fig 3. Kaplan-Meier analysis for overall survival and progression-free survival according to metastatic status. Fig (a): Overall survival in patients with CRC, metastatic vs. non-metastatic disease. Fig (b): Progression-free survival in patients with CRC, metastatic vs. non-metastatic disease. *P*-value Indicates significance according to Log-Rank (Mantel-Cox) test when mCRC is compared to non-mCRC.

	Log-Rank (Mantel-Cox)	
	Chi-square	*p*-value
Figure a (OS)	0.047	0.829
Figure b (PFS)	0.024	0.876

Fig 4. Kaplan-Meier analysis for overall survival and progression-free survival according to the postoperative CTCs. Fig (a): Overall survival in patients with CRC, positive vs. negative postoperative CTCs. Fig (b): Progression-free survival in patients with CRC, positive vs. negative postoperative CTCs. *P*-value Indicates significance according to Log-Rank (Mantel-Cox) test when CTC-negative patients are compared with CTC-positive patients postoperatively.

https://doi.org/10.1371/journal.pone.0252897.g004

[21]. CTC identification has proven to be an important prognosticator in breast cancer [22]. For this reason, a decade ago, the 7th AJCC Cancer Staging Manual introduced the new category M0(i) for breast cancer, which is defined by the presence of circulating or disseminated tumor cells not exceeding 0.2 mm detectable in bone marrow, circulating blood, or other non-regional tissues of non-metastatic patients. In contrast, such a category is still lacking in the current CRC Staging system [23], this is because the assessment of CTCs in CRC is still

Table 3. Univariate and multivariate analysis of overall survival in patients with CRC.

	Univariate Analysis			Multivariate Analysis		
	HR	95% CI	*p*	HR	95% Cl	*p*
Age, <65,65–74, ≥75	2.95	1.50–5.80	0.002	2.85	1.51–5.38	0.001
Sex, male vs female	0.833	0.37–1.87	0.650	1.12	0.49–2.52	0.784
Grade of Differentiation, G1-3	1.30	0.51–3.33	0.585			
T, T1-T4	1.26	0.73–2.19	0.392			
N, N0- N2	1.09	0.67–1.78	0.710			
Metastatic stage, M0 vs M1	3.01	1.11–8.20	0.019	2.54	0.30–21.16	0.388
UICC Stage	2.20	1.15–4.18	0.016	1.04	0.33–3.33	0.938
Preoperative CTCs, neg vs pos	2.85	1.25–6.46	0.012	3.14	1.18–8.32	0.021
Postoperative CTCs, neg vs pos	1.53	0.43–5.51	0.515			

p Indicates significance according to cox regression analysis comparing the specified variables. HR indicates hazard ratio.

https://doi.org/10.1371/journal.pone.0252897.t003

controversial [16] and different technical platforms have provided conflicting results [24–26]. Here, we applied the FDA-cleared Cellsearch® system, which uses immunomagnetic enrichment (EpCAM) and immunocytochemical (cytokeratin, CD45, DAPI) fluorescence analysis. The epithelial cell adhesion molecule (EpCAM) was first identified in colon cancer in 1979 [27]. It is expressed by a variety of epithelial cells, is highly expressed in colorecal cancer cells [28] and is known to promote tumor expansion and oncogenesis [29]. Thus EpCAM is widely used to capture and detect CTCs. During the process of dissemination and metastasis, tumor cells undergo epithelial-mesenchymal transition (EMT) and might lose their epithelial cell features including EpCAM and/or keratin expression. CTCs that have completely downregulated these epithelial properties are not detectable with the CellSearch system (CS) and require marker-free enrichment methods such as size-, plasticity-, or density-based approaches (Alix-Panabieres C and Pantel K Cancer Discovery 2021) for their identification [30, 31]. Nevertheless, the CellSearch system (CS) which based on EpCAM-related capture of CTCs is standardized, time-efficient and provides clinically relevant results for CTC detection in a wide range of carcinoma patients [31–33]. Several studies have addressed the detectability of CTCs and their prognostic impact in mCRC using CS. According to Cohen et al., CTCs detected using CS provide additional information about tumor burden to imaging studies and therefore have gained a prognostic and predictive value in guiding treatment of mCRC [12]. In addition, Bork et al. showed that CTCs were detectable using CS in patients with CRC (I-III). CTCs were detectable even in patients without nodal or distant metastasis at time of operation (UICC I-II), which was associated with worse survival outcome [34]. In our cohort CTCs were detectable in 45.6% of the patients before surgical resection and were present in all stages of CRC (I-IV). Even in early-stage CRC, UICC I (T1-2, N0, M0), 25% of patients were CTC-positive.

Up to now, there is no consensus regarding the threshold used to define CTC positivity in CRC [16]. Cohen et al have used the cut-off of $\geq$ 3 CTC/7.5 ml for defining CTC positivity in metastatic CRC [12], while others have shown that cut-offs $\geq$1 CTC/7.5 ml and $\geq$ 2 CTC/7.5 ml were also associated with poor prognosis in CRC [35, 36]. We used a strict cut-off of $\geq$1 CTC/7.5 ml. CTC detection before surgery was associated significantly with a shorter progression-free (P = 0.008) and overall survival (P = 0.008). Multivariate analyses identified CTCs as a strong, independent, prognostic indicator for overall survival.

Many studies have shown inferior survival for right-sided tumors [37, 38], which has prompted us to assess the effect of tumor location on CTC detection. Right-sided colon cancer (RCC), left-sided colon cancer (LCC), and rectal cancer (RC) were considered independently [39–41]. Although more CTCs were present in LCC compared to RCC and RC, there was not a statistically significant correlation. A previous publication from Nicolazzo et al. showed similar results [39]. However, larger cohorts are needed to deliver a robust conclusion about tumor sidedness and CTC detection.

From a clinical perspective, using CTCs in peripheral blood allows assessing cancer prognosis in a non-invasive and easily applicable method [16] that allows real-time monitoring of tumor dynamics [42]. Our present study supports the assumption that preoperative CTC detection in CRC identifies patients with shorter OS and PFS, which might contribute to an improved stratification of high-risk CRC patients. Nevertheless, larger validation studies are required before the implementation of CTC detection into tumor staging classification of CRC.

Conclusion

Preoperative CTC detection is an important prognostic marker for survival in CRC, which can be further developed as an enrichment tool to study a high-risk population of CRC patients in clinical trials.

Supporting information

S1 Data. Patients histopathological and survival data.
(SAV)

Author Contributions

Conceptualization: Klaus Pantel, Matthias Reeh.

Data curation: Jan Meiners, Karl-F. Karstens.

Formal analysis: Thaer S. A. Abdalla.

Investigation: Sabine Riethdorf, Tobias Gorges, Klaus Pantel.

Supervision: Alexandra König, Nathaniel Melling, Jakob R. Izbicki, Matthias Reeh.

Writing – original draft: Thaer S. A. Abdalla.

Writing – review & editing: Sabine Riethdorf, Klaus Pantel, Matthias Reeh.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021. Epub 2021/02/05. https://doi.org/10.3322/caac.21660 PMID: 33538338.

2. Allemani C, Rachet B, Weir HK, Richardson LC, Lepage C, Faivre J, et al. Colorectal cancer survival in the USA and Europe: a CONCORD high-resolution study. BMJ open. 2013; 3(9):e003055. Epub 2013/09/12. https://doi.org/10.1136/bmjopen-2013-003055 PMID: 24022388; PubMed Central PMCID: PMC3773629.

3. Strey CW, Wullstein C, Adamina M, Agha A, Aselmann H, Becker T, et al. Laparoscopic right hemico-lectomy with CME: standardization using the "critical view" concept. Surgical endoscopy. 2018; 32 (12):5021–30. Epub 2018/10/17. https://doi.org/10.1007/s00464-018-6267-0 PMID: 30324463; PubMed Central PMCID: PMC6208708.

4. Lirici MM, Hüscher CG. Techniques and technology evolution of rectal cancer surgery: a history of more than a hundred years. Minimally invasive therapy & allied technologies: MITAT: official journal of the Society for Minimally Invasive Therapy. 2016; 25(5):226–33. Epub 2016/07/15. https://doi.org/10.1080/13645706.2016.1198381 PMID: 27415777.

5. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic can-cer: complete mesocolic excision and central ligation—technical notes and outcome. Colorectal Dis. 2009; 11(4):354–64; discussion 64–5. Epub 2008/11/20. https://doi.org/10.1111/j.1463-1318.2008.01735.x PMID: 19016817.

6. Heald RJ, Santiago I, Pares O, Carvalho C, Figueiredo N. The Perfect Total Mesorectal Excision Obvi-ates the Need for Anything Else in the Management of Most Rectal Cancers. Clinics in colon and rectal surgery. 2017; 30(5):324–32. Epub 2017/12/01. https://doi.org/10.1055/s-0037-1606109 PMID: 29184467; PubMed Central PMCID: PMC5703664.

7. Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology. 2013; 24 Suppl 6:vi64–72. Epub 2013/10/23. https://doi.org/10.1093/annonc/mdt354 PMID: 24078664.

8. Young PE, Womeldorph CM, Johnson EK, Maykel JA, Brucher B, Stojadinovic A, et al. Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. Journal of Cancer. 2014; 5(4):262–71. Epub 2014/05/03. https://doi.org/10.7150/jca.7988 PMID: 24790654; PubMed Central PMCID: PMC3982039.

9. Liberko M, Kolostova K, Bobek V. Essentials of circulating tumor cells for clinical research and practice. Critical reviews in oncology/hematology. 2013; 88(2):338–56. Epub 2013/07/09. https://doi.org/10.1016/j.critrevonc.2013.05.002 PMID: 23830807.

10. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. The New England journal of medicine. 2004; 351 (8):781–91. Epub 2004/08/20. https://doi.org/10.1056/NEJMoa040766 PMID: 15317891.

11. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, et al. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302–9. Epub 2008/10/03. https://doi.org/10.1158/1078-0432.CCR-08-0872 PMID: 18829513.

12. Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, et al. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2008; 26(19):3213–21. Epub 2008/07/02. https://doi.org/10.1200/jco.2007.15.8923 PMID: 18591556.

13. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol. 2018; 25(6):1454–5. Epub 2018/04/05. https://doi.org/10.1245/s10434-018-6462-1 PMID: 29616422.

14. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM. Annals of Surgical Oncology. 2010; 17(6):1471–4. https://doi.org/10.1245/s10434-010-0985-4 WOS:000277594300001. PMID: 20180029

15. Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science translational medicine. 2016; 8(346):346ra92. Epub 2016/07/08. https://doi.org/10.1126/scitranslmed.aaf6219 PMID: 27384348; PubMed Central PMCID: PMC5346159.

16. Huang X, Gao P, Song Y, Sun J, Chen X, Zhao J, et al. Meta-analysis of the prognostic value of circulating tumor cells detected with the CellSearch System in colorectal cancer. BMC cancer. 2015; 15:202. Epub 2015/04/17. https://doi.org/10.1186/s12885-015-1218-9 PMID: 25880692; PubMed Central PMCID: PMC4389311.

17. Pox C, Aretz S, Bischoff SC, Graeven U, Hass M, Heussner P, et al. [S3-guideline colorectal cancer version 1.0]. Z Gastroenterol. 2013; 51(8):753–854. Epub 2013/08/21. https://doi.org/10.1055/s-0033-1350264 PMID: 23955142.

18. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res. 2004; 10(20):6897–904. Epub 2004/10/27. https://doi.org/10.1158/1078-0432.CCR-04-0378 PMID: 15501967.

19. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920–8. Epub 2007/02/10. https://doi.org/10.1158/1078-0432.CCR-06-1695 PMID: 17289886.

20. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer. 2003; 3(6):453–8. https://doi.org/10.1038/nrc1098 PMID: 12778135

21. Hoeppner J, Kulemann B. Circulating Tumor Cells in Esophageal Cancer. Oncology research and treatment. 2017; 40(7–8):417–22. Epub 2017/07/12. https://doi.org/10.1159/000478863 PMID: 28693013.

22. Giuliano M, Giordano A, Jackson S, De Giorgi U, Mego M, Cohen EN, et al. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. Breast cancer research: BCR. 2014; 16(5):440. Epub 2014/09/17. https://doi.org/10.1186/s13058-014-0440-8 PMID: 25223629; PubMed Central PMCID: PMC4303121.

23. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010; 17(6):1471–4. Epub 2010/02/25. https://doi.org/10.1245/s10434-010-0985-4 PMID: 20180029.

24. Kuvendjiska J, Bronsert P, Martini V, Lang S, Pitman MB, Hoeppner J, et al. Non-Metastatic Esophageal Adenocarcinoma: Circulating Tumor Cells in the Course of Multimodal Tumor Treatment. Cancers. 2019; 11(3). Epub 2019/03/25. https://doi.org/10.3390/cancers11030397 PMID: 30901891; PubMed Central PMCID: PMC6468610.

25. Yang C, Zou K, Zheng L, Xiong B. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review. BMC cancer. 2017; 17(1):725. Epub 2017/11/09. https://doi.org/10.1186/s12885-017-3704-8 PMID: 29115932; PubMed Central PMCID: PMC5688806.

26. Vojtechova G, Benesova L, Belsanova B, Minarikova P, Levy M, Lipska L, et al. Monitoring of Circulating Tumor Cells by a Combination of Immunomagnetic Enrichment and RT-PCR in Colorectal Cancer Patients Undergoing Surgery. Advances in clinical and experimental medicine: official organ Wroclaw Medical University. 2016; 25(6):1273–9. Epub 2016/12/29. https://doi.org/10.17219/acem/63824 PMID: 28028983.

27. Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. 1979; 76(3):1438–42. https://doi.org/10.1073/pnas.76.3.1438%J Proceedings of the National Academy of Sciences. PMID: 286328

28. Went PTH, Lugli A, Meier S, Bundi M, Mirlacher M, Sauter G, et al. Frequent EpCam protein expression in human carcinomas. Human Pathology. 2004; 35(1):122–8. https://doi.org/10.1016/j.humpath.2003.08.026 PMID: 14745734

29. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, et al. Nuclear signalling by tumour-associated antigen EpCAM. Nature Cell Biology. 2009; 11(2):162–71. https://doi.org/10.1038/ncb1824 PMID: 19136966

30. Gorges TM, Tinhofer I, Drosch M, Röse L, Zollner TM, Krahn T, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC cancer. 2012; 12 (1):178. https://doi.org/10.1186/1471-2407-12-178 PMID: 22591372

31. Riethdorf S, O'Flaherty L, Hille C, Pantel K. Clinical applications of the CellSearch platform in cancer patients. Advanced drug delivery reviews. 2018; 125:102–21. Epub 2018/01/23. https://doi.org/10.1016/j.addr.2018.01.011 PMID: 29355669.

32. Riethdorf S, Fritsche H, Müller V, Rau T, Schindlbeck C, Rack B, et al. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res. 2007; 13(3):920–8. Epub 2007/02/10. https://doi.org/10.1158/1078-0432.CCR-06-1695 PMID: 17289886.

33. Alix-Panabières C, Pantel K. Liquid Biopsy: From Discovery to Clinical Application. Cancer discovery. 2021; 11(4):858–73. Epub 2021/04/04. https://doi.org/10.1158/2159-8290.CD-20-1311 PMID: 33811121.

34. Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015; 112 (8):1306–13. Epub 2015/04/14. https://doi.org/10.1038/bjc.2015.88 PMID: 25867263; PubMed Central PMCID: PMC4402459.

35. Seeberg LT, Waage A, Brunborg C, Hugenschmidt H, Renolen A, Stav I, et al. Circulating tumor cells in patients with colorectal liver metastasis predict impaired survival. Ann Surg. 2015; 261(1):164–71. Epub 2014/02/11. https://doi.org/10.1097/SLA.0000000000000580 PMID: 24509211.

36. Gazzaniga P, Raimondi C, Gradilone A, Biondi Zoccai G, Nicolazzo C, Gandini O, et al. Circulating tumor cells in metastatic colorectal cancer: do we need an alternative cutoff? Journal of cancer research and clinical oncology. 2013; 139(8):1411–6. Epub 2013/06/06. https://doi.org/10.1007/s00432-013-1450-0 PMID: 23736274.

37. Lee MM, MacKinlay A, Semira C, Schieber C, Jimeno Yepes AJ, Lee B, et al. Stage-based Variation in the Effect of Primary Tumor Side on All Stages of Colorectal Cancer Recurrence and Survival. Clinical colorectal cancer. 2018; 17(3):e569–e77. Epub 2018/07/08. https://doi.org/10.1016/j.clcc.2018.05.008 PMID: 29980491.

38. Mendis S, Beck S, Lee B, Lee M, Wong R, Kosmider S, et al. Right versus left sided metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival. Asia-Pacific journal of clinical oncology. 2019; 15(3):136–43. Epub 2019/02/15. https://doi.org/10.1111/ajco.13135 PMID: 30761750.

39. Nicolazzo C, Raimondi C, Gradilone A, Emiliani A, Zeuner A, Francescangeli F, et al. Circulating Tumor Cells in Right- and Left-Sided Colorectal Cancer. Cancers. 2019; 11(8). Epub 2019/07/28. https://doi.org/10.3390/cancers11081042 PMID: 31344798; PubMed Central PMCID: PMC6721440.

40. Salem ME, Yin J, Renfro LA, Weinberg BA, Maughan T, Adams R, et al. Rectal versus left-sided colon cancers: Clinicopathological differences observed in a pooled analysis of 4,182 patients enrolled to 8 clinical trials from the ARCAD database. Journal of Clinical Oncology. 2017; 35(4_suppl):675–. https://doi.org/10.1200/JCO.2017.35.4_suppl.675

41. Li FY, Lai MD. Colorectal cancer, one entity or three. Journal of Zhejiang University Science B. 2009; 10 (3):219–29. Epub 2009/03/14. https://doi.org/10.1631/jzus.B0820273 PubMed Central PMCID: PMC2650032. PMID: 19283877

42. Junqueira-Neto S, Batista IA, Costa JL, Melo SA. Liquid Biopsy beyond Circulating Tumor Cells and Cell-Free DNA. Acta cytologica. 2019; 63(6):479–88. Epub 2019/02/21. https://doi.org/10.1159/000493969 PMID: 30783027.